David Miller, MD
Allergy · Pittsburgh, PANPI 1538117486
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 371 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,555, more than ten times the $35 reported in 2020.
Across 371 payments — averaging $19.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$1K
- AstraZeneca$1K
- GSK$916
- Sanofi$503
- Grifols USA, LLC$454
- Biocryst US Sales Co., LLC$454
- plus $3K from 25 others
Across 27 payments — averaging $6886.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$91K
- GSK$54K
- Incyte Corporation$41K
What the payments were for
- Consulting fees$210%
- Food & beverage$7,31299%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 50 | $1,258 |
| AstraZeneca | 62 | $1,221 |
| GSK | 64 | $916 |
| Sanofi | 25 | $503 |
| Grifols USA, LLC | 22 | $454 |
| Biocryst US Sales Co., LLC | 27 | $454 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $402 |
| CSL Behring | 18 | $385 |
| Genentech USA, Inc. | 16 | $364 |
| Pfizer | 12 | $235 |
| Amgen | 12 | $222 |
| ARS Pharmaceuticals Operations, Inc. | 12 | $147 |
| Novartis | 5 | $135 |
| Baxter Healthcare | 1 | $118 |
| Kaleo, Inc. | 5 | $77 |
| Optinose US, Inc. | 4 | $69 |
| Vifor Pharma, Inc. | 3 | $58 |
| Dexcom, Inc. | 2 | $46 |
| Incyte Corporation | 2 | $45 |
| Apellis Pharmaceuticals, Inc. | 1 | $34 |
| Merck | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Pharming Healthcare, Inc. | 1 | $24 |
| ADMA Biomanufacturing LLC | 1 | $21 |
| Biocryst Pharmaceuticals, Inc. | 1 | $19 |
| Verona Pharma, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Octapharma USA, Inc. | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Ionis Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARTISS$118
How this compares
$7,355 in reported general payments places this provider in the 75th percentile of 25 allergy providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $46,498 |
| Breo ElliptaFluticasone/Vilanterol | 75 | $43,226 |
| Qvar RedihalerBeclomethasone Dipropionate | 49 | $21,139 |
| Arnuity ElliptaFluticasone Furoate | 53 | $19,181 |
| Fluticasone Propionate HfaFluticasone Propionate | 40 | $17,893 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $9,863 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 49 | $8,231 |
| Epinephrine | 30 | $7,257 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 157 | $6,763 |
| Fluticasone Propionate | 197 | $6,581 |
| Azelastine Hcl | 164 | $5,143 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 17 | $4,620 |
| Mometasone Furoate | 39 | $3,135 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 14 | $1,905 |
| Montelukast Sodium | 138 | $1,876 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $916 | $108,906176 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $24 | $21,13949 claims |
| AstraZenecaSymbicort | $1,221 | $9,86321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 25 allergy providers in Pennsylvania.
Other allergy in Pittsburgh
- Michael PalumboPittsburgh$561K
- James DeangeloPittsburgh$79K
- Allyson LarkinPittsburgh$1K
- Richard GreenPittsburgh$139
- Andrew VayonisPittsburgh$15
- Shannon KearneyBethlehem$48K
- Rehan MujahidWind Gap$16K
- Schweta ArakaliAllentown$12K
- Michelle WeissYork$7K
- Andrew MurphyWest Chester$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.